Apogee Therapeutics secured a $1.3 billion royalty financing deal with Blackstone Life Sciences to take zumilokibart through commercialization. Shares fell ~11% before Wednesday’s open.
The deal’s terms in Apogee’s 8-K: $800 million in synthetic royalties plus a $500 million senior debt option. Blackstone gets up to a 6.25% royalty on the first $5 billion in worldwide annual sales, dropping to 1.7% at $20 billion. Apogee collects $400 million in pre-approval tranches: $100 million at signing, $100 million at Phase 3 enrollment, $200 million on positive Phase 3 data.
Combined with Apogee’s existing $1.3 billion cash, this is the largest royalty financing ever for a pre-Phase 3 program. With the capital secured, Apogee can pursue zumilokibart across AD, asthma, and eosinophilic esophagitis without returning to equity markets.
Phase 2 APEX Part B results showed zumilokibart’s mid-dose hitting 65.9% EASI-75 at 16 weeks versus 23.4% placebo; the high dose clocked 61.6%. The mid-dose tracks Lilly’s Ebglyss, the current AD standard of care. Henderson called the structure “a no-brainer” given a change-of-control provision for royalty buyback.
Royalty financing at this scale doesn’t happen for pre-Phase 3 programs. Apogee can now fund through launch without equity dilution, and Henderson says strategic optionality is fully preserved. But any acquirer now faces a two-party balance sheet: Apogee’s share plus Blackstone’s royalty stake, and that’s the friction the market priced in Wednesday, not the drug.
Phase 3 for atopic dermatitis launches H2 2026, with a 2029 commercial target.
Sarah Chen